Sativex Can Improve Driving Ability of MS Patients, Study Says

Sativex Can Improve Driving Ability of MS Patients, Study Says

Sativex, a cannabis-based anti-spasticity medicine commercialized as oromucosal spray by GW Pharmaceuticals, improves the driving ability of patients with multiple sclerosis (MS), according to researchers.

The findings were published in the journal Brain and Behavior, in a study titled “The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

Driving is an important task to help MS patients maintain the activities of daily living, including their independence, social interactions and access to work, healthcare, family and shopping.

However, MS is associated with physical, sensory and cognitive disabilities, like muscle spasticity or visual and auditory impairment, that may affect the daily living functions of patients.

Some MS treatments also are known to negatively affect the driving ability of patients. Disease-modifying drugs (DMDs), corticosteroids, and other medicines used to manage symptoms like depression, anxiety, pain and muscle spasticity, affect patients’ driving performance, including wakefulness, coordination, reaction times, and concentration.

In the study, researchers reviewed the effects of using Sativex on the driving performance of MS patients. Sativex is an oromucosal spray combining two of the most common types of cannabinoids —  tetrahydrocannabinol (THC) and cannabidiol (CBD).

Sativex is approved across the European Union and in other countries as a second-line therapy for adult patients with moderate-to-severe MS-related spasticity that is resistant to first-line anti-spasticity medications, such as Lioseral.

Researchers consulted published research articles, from January 2000 to June 2017, that focused on this theme.

The analysis revealed that Sativex use did not increase the number of motor vehicle accidents reported. In fact, most of the patients analyzed showed an improvement in driving ability after starting Sativex treatment.

Such improvements could be related to a reduced spasticity and/or better cognitive function as a result of cannabinoids’ consumption, the researchers suggested.

“THC:CBD oromucosal spray was shown not to impair driving performance. However, periodic assessment of patients with MS driving ability is recommended, especially after relapses and changes in treatment,” the researchers wrote.

The team highlighted that THC levels in the blood of patients using Sativex were significantly lower than the ones measured after recreational use of herbal cannabis. Each 100 microliters of spray contains 2.7 milligrams of THC and 2.5 milligrams of CBD. Nevertheless, these levels might be above the authorized limit in some countries.

“Blood THC measurements might be above authorized thresholds for some countries following administration of THC:CBD oromucosal spray, thus specific knowledge of each country’s driving regulations and a medical certificate are recommended,” the team advised.

7 comments

  1. Reginald E Bavis says:

    How can she say that she was lucky having ms. I think that she should have this kind of care from Doctors .

  2. Crystal Brickell says:

    I am very interested in Sativex spray. I gave up my license because of my MS a couple years ago due to some of my symptoms. I would love to be able to at least try it.🤗

    • Grant Madden says:

      Check out New Zealand stem cell clinic.They could be very beneficial for you.I think the younger you are,the better are the results.Made a small but positive result so far from first try.Am going to get another session.Will see then but I’m 62 so border line results.Clean and drug free therapy.Fast and easy to do too.

  3. Becky Stroebel says:

    I’m interested in hearing more about Sativex spray. Does it actually improve a person’s driving ability?

  4. Annette Poche says:

    I would also like more information on the Sativex spray. I haven’t driven in 15 years. I’m tired of having to rely on other people to do simple errands.

Leave a Comment

Your email address will not be published. Required fields are marked *